Cover Image
Market Research Report
Product code 
1110447

Biosimilars Market (Product: Recombinant Glycosylated Proteins, Recombinant Non-glycosylated Proteins, and Recombinant Peptides) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031

Published: | Transparency Market Research | 232 Pages | Delivery time: 1-2 business days

Price

Back to Top
Biosimilars Market (Product: Recombinant Glycosylated Proteins, Recombinant Non-glycosylated Proteins, and Recombinant Peptides) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031
Published: June 7, 2022
Transparency Market Research
Content info: 232 Pages
Delivery time: 1-2 business days
  • Description
  • Table of Contents
  • List of Tables

Biosimilars Market - Scope of Report

TMR's report on the global biosimilars market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2022 to 2031. The report provides revenue of the global biosimilars market for the period 2017-2031, considering 2021 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global biosimilars market from 2022 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the biosimilars market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global biosimilars market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report sheds light on the changing competitive dynamics in the global biosimilars market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global biosimilars market.

The report delves into the competitive landscape of the global biosimilars market. Key players operating in the global biosimilars market have been identified and each one of these has been profiled, in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are attributes of players in the global biosimilars market profiled in this report.

RESEARCH METHODOLOGY

The research methodology will be a combination of exhaustive primary and secondary research to analyze the market biosimilars.

Secondary Research

Secondary research includes a search of company literature, technical writing, patent data, Internet sources, and statistical data from government websites, trade associations, and agencies. This has proven to be the most reliable, effective, and successful approach for obtaining precise data, capturing industry participants' insights, and recognizing business opportunities.

Secondary research sources that we typically refer, but are not limited to:

  • Company websites, presentations, annual reports, white papers, technical paper, product brochure
  • Internal and external proprietary databases and relevant patents
  • National government documents, statistical databases, and market reports
  • News articles, press releases, and webcasts specific to companies operating in the market

Specific Secondary Sources:

Industry Sources:

  • WorldWideScience.org
  • Elsevier, Inc.
  • National Institutes of Health (NIH)
  • PubMed
  • NCBI
  • Department of Health Care Service
  • Trade Data Sources
  • Trade Map
  • UN Comtrade
  • Trade Atlas
  • Company Information
  • OneSource Business Browser
  • Hoover's
  • Factiva
  • Bloomberg
  • Mergers & Acquisitions
  • Thomson Mergers & Acquisitions
  • MergerStat
  • Profound
  • Primary Research
  • During the course of research, we conduct in-depth interviews and discussions with a wide range of key industry participants and opinion leaders. Primary research represents bulk of research efforts, supplemented by extensive secondary research.

We conduct primary interviews on the ongoing basis with industry participants and commentators to validate data and analysis. A typical research interview fulfills the following functions:

  • Provides first-hand information on market size, market trends, growth trends, competitive landscape, outlook, etc.
  • Helps in validating and strengthening secondary research findings
  • Further develops the analysis team's expertise and market understanding
  • Primary research involves e-mail interactions, telephonic interviews, as well as face-to-face interviews for each market, category, segment, and sub-segment across geographies

Participants who typically take part in such a process include, but are not limited to:

  • Industry participants: Marketing/product managers, market intelligence managers, and regional sales managers
  • Purchasing/Sourcing managers, technical personnel, distributors
  • Outside experts: Investment bankers, valuation experts, and research analysts specializing in specific markets
  • Key opinion leaders specializing in different areas corresponding to different industry verticals

List of primary participants, but not limited to:

  • Advanced Oncotherapy PLC
  • Danfysik A/S
  • Hitachi, Ltd.
  • IBA Worldwide
  • Mevion Medical Systems, Inc.
  • Data Triangulation: Information culled from "Secondary & Primary Sources" is cross-checked with "TMR Knowledge Repository", which is updated every quarter.

Market Estimation: Market size estimations involved in-depth study of product features, technology updates, geographic presence, product demand, sales data (value or volume), historical year-on-year growth, and others. Other approaches were also utilized to derive market size and forecasts. Where no hard data was available, we employed modeling techniques in order to produce comprehensive datasets. A rigorous methodology has been adopted, wherein the available hard data are cross-referenced with the following data types to produce estimates:

  • Demographic Data: Healthcare expenditure, inflation rates, and others
  • Industry Indicators: R&D investment, technology stage, and infrastructure, sector growth, and facilities
  • Market Forecasting: Market forecasts for various segments are derived taking into account drivers, restraints/challenges, and opportunities prevailing in the market and considering advantages/disadvantages of segments/sub-segments over other segments/sub-segments. Business environment, historical sales pattern, unmet needs, competitive intensity, and country-wise surgery data are some of the other pivotal factors, which are considered to derive market forecasts.
Product Code: TMRGL118

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Acronyms

3. Research Methodology

4. Executive Summary: Global Biosimilars Market

5. Market Overview

  • 5.1. Definition
  • 5.2. Market Indicators
  • 5.3. Market Dynamics
    • 5.3.1. Drivers
    • 5.3.2. Restraints
    • 5.3.3. Opportunities

6. Market Outlook

  • 6.1. Global Biosimilars Market Analysis and Forecast, 2017-2031
  • 6.2. Global Biosimilars Market Outlook
  • 6.3. Entry Barriers to Biosimilars Market
  • 6.4. Factors Driving the Adoption of Biosimilars
  • 6.5. Pipeline Analysis
  • 6.6. Regulatory Scenario Assessment
  • 6.7. Key Industry Developments

7. Global Biosimilars Market Analysis and Forecast, by Product

  • 7.1. Introduction
  • 7.2. Biosimilars Market Value Forecast, by Product, 2017-2031
    • 7.2.1. Recombinant Glycosylated Proteins
      • 7.2.1.1. Monoclonal Antibodies
      • 7.2.1.2. Erythropoietin
      • 7.2.1.3. Others
    • 7.2.2. Recombinant Non-glycosylated Proteins
      • 7.2.2.1. Insulin
      • 7.2.2.2. Granulocyte Colony Stimulating Factor
      • 7.2.2.3. Recombinant Human Growth Factor
      • 7.2.2.4. Interferons
    • 7.2.3. Recombinant Peptides
  • 7.3. Market Attractiveness Analysis, by Product

8. Global Biosimilars Market Analysis and Forecast, by Indication

  • 8.1. Introduction
  • 8.2. Biosimilars Market Value Forecast, by Indication, 2017-2031
    • 8.2.1. Chronic Diseases
    • 8.2.2. Oncology
    • 8.2.3. Autoimmune Diseases
    • 8.2.4. Infectious Diseases
    • 8.2.5. Blood Disorders
    • 8.2.6. Growth Hormone Deficiency
    • 8.2.7. Others
  • 8.3. Market Attractiveness Analysis, by Material

9. Global Biosimilars Market Analysis and Forecast, by Region

  • 9.1. Regional Outlook
  • 9.2. Global Scenario
  • 9.3. Introduction
  • 9.4. Biosimilars Market Value Forecast, by Region
    • 9.4.1. North America
    • 9.4.2. Europe
    • 9.4.3. Asia Pacific
    • 9.4.4. Latin America
    • 9.4.5. Middle East & Africa
  • 9.5. Market Attractiveness Analysis, by Region

10. North America Biosimilars Market Analysis and Forecast

  • 10.1. Key Findings
  • 10.2. North America Biosimilars Market Value Forecast, by Product, 2017-2031
    • 10.2.1. Recombinant Glycosylated Proteins
      • 10.2.1.1. Monoclonal Antibodies
      • 10.2.1.2. Erythropoietin
      • 10.2.1.3. Others
    • 10.2.2. Recombinant Non-glycosylated Proteins
      • 10.2.2.1. Insulin
      • 10.2.2.2. Granulocyte Colony Stimulating Factor
      • 10.2.2.3. Recombinant Human Growth Factor
      • 10.2.2.4. Interferons
    • 10.2.3. Recombinant Peptides
  • 10.3. North America Biosimilars Market Value Forecast, by Indication, 2017-2031
    • 10.3.1. Chronic Diseases
    • 10.3.2. Oncology
    • 10.3.3. Autoimmune Diseases
    • 10.3.4. Infectious Diseases
    • 10.3.5. Blood Disorders
    • 10.3.6. Growth Hormone Deficiency
    • 10.3.7. Others
  • 10.4. North America Biosimilars Market Value Forecast, by Country, 2017-2031
    • 10.4.1. U.S.
    • 10.4.2. Canada
  • 10.5. North America Biosimilars Market Attractiveness Analysis
    • 10.5.1. By Product
    • 10.5.2. By Indication
    • 10.5.3. By Country

11. Europe Biosimilars Market Analysis and Forecast

  • 11.1. Key Findings
  • 11.2. Europe Biosimilars Market Value Forecast, by Product, 2017-2031
    • 11.2.1. Recombinant Glycosylated Proteins
      • 11.2.1.1. Monoclonal Antibodies
      • 11.2.1.2. Erythropoietin
      • 11.2.1.3. Others
    • 11.2.2. Recombinant Non-glycosylated Proteins
      • 11.2.2.1. Insulin
      • 11.2.2.2. Granulocyte Colony Stimulating Factor
      • 11.2.2.3. Recombinant Human Growth Factor
      • 11.2.2.4. Interferons
    • 11.2.3. Recombinant Peptides
  • 11.3. Europe Biosimilars Market Value Forecast, by Indication, 2017-2031
    • 11.3.1. Chronic Diseases
    • 11.3.2. Oncology
    • 11.3.3. Autoimmune Diseases
    • 11.3.4. Infectious Diseases
    • 11.3.5. Blood Disorders
    • 11.3.6. Growth Hormone Deficiency
    • 11.3.7. Others
  • 11.4. Europe Biosimilars Market Value Forecast, by Country/Sub-region, 2017-2031
    • 11.4.1. U.K.
    • 11.4.2. Germany
    • 11.4.3. France
    • 11.4.4. Italy
    • 11.4.5. Spain
    • 11.4.6. Rest of Europe
  • 11.5. Europe Biosimilars Market Attractiveness Analysis
    • 11.5.1. By Product
    • 11.5.2. By Indication
    • 11.5.3. By Country/Sub-region

12. Asia Pacific Biosimilars Market Analysis and Forecast

  • 12.1. Key Findings
  • 12.2. Asia Pacific Biosimilars Market Value Forecast, by Product, 2017-2031
    • 12.2.1. Recombinant Glycosylated Proteins
      • 12.2.1.1. Monoclonal Antibodies
      • 12.2.1.2. Erythropoietin
      • 12.2.1.3. Others
    • 12.2.2. Recombinant Non-glycosylated Proteins
      • 12.2.2.1. Insulin
      • 12.2.2.2. Granulocyte Colony Stimulating Factor
      • 12.2.2.3. Recombinant Human Growth Factor
      • 12.2.2.4. Interferons
    • 12.2.3. Recombinant Peptides
  • 12.3. Asia Pacific Biosimilars Market Value Forecast, by Indication, 2017-2031
    • 12.3.1. Chronic Diseases
    • 12.3.2. Oncology
    • 12.3.3. Autoimmune Diseases
    • 12.3.4. Infectious Diseases
    • 12.3.5. Blood Disorders
    • 12.3.6. Growth Hormone Deficiency
    • 12.3.7. Others
  • 12.4. Asia Pacific Biosimilars Market Value Forecast, by Country/Sub-region, 2017-2031
    • 12.4.1. China
    • 12.4.2. India
    • 12.4.3. Japan
    • 12.4.4. Australia & New Zealand
    • 12.4.5. Rest of Asia Pacific
  • 12.5. Asia Pacific Biosimilars Market Attractiveness Analysis
    • 12.5.1. By Product
    • 12.5.2. By Indication
    • 12.5.3. By Country/Sub-region

13. Latin America Biosimilars Market Analysis and Forecast

  • 13.1. Key Findings
  • 13.2. Latin America Biosimilars Market Value Forecast, by Product, 2017-2031
    • 13.2.1. Recombinant Glycosylated Proteins
      • 13.2.1.1. Monoclonal Antibodies
      • 13.2.1.2. Erythropoietin
      • 13.2.1.3. Others
    • 13.2.2. Recombinant Non-glycosylated Proteins
      • 13.2.2.1. Insulin
      • 13.2.2.2. Granulocyte Colony Stimulating Factor
      • 13.2.2.3. Recombinant Human Growth Factor
      • 13.2.2.4. Interferons
    • 13.2.3. Recombinant Peptides
  • 13.3. Latin America Biosimilars Market Value Forecast, by Indication, 2017-2031
    • 13.3.1. Chronic Diseases
    • 13.3.2. Oncology
    • 13.3.3. Autoimmune Diseases
    • 13.3.4. Infectious Diseases
    • 13.3.5. Blood Disorders
    • 13.3.6. Growth Hormone Deficiency
    • 13.3.7. Others
  • 13.4. Latin America Biosimilars Market Value Forecast, by Country/Sub-region, 2017-2031
    • 13.4.1. Brazil
    • 13.4.2. Mexico
    • 13.4.3. Rest of Latin America
  • 13.5. Latin America Biosimilars Market Attractiveness Analysis
    • 13.5.1. By Product
    • 13.5.2. By Indication
    • 13.5.3. By Country/Sub-region

14. Middle East & Africa Biosimilars Market Analysis and Forecast

  • 14.1. Key Findings
  • 14.2. Middle East & Africa Biosimilars Market Value Forecast, by Product, 2017-2031
    • 14.2.1. Recombinant Glycosylated Proteins
      • 14.2.1.1. Monoclonal Antibodies
      • 14.2.1.2. Erythropoietin
      • 14.2.1.3. Others
    • 14.2.2. Recombinant Non-glycosylated Proteins
      • 14.2.2.1. Insulin
      • 14.2.2.2. Granulocyte Colony Stimulating Factor
      • 14.2.2.3. Recombinant Human Growth Factor
      • 14.2.2.4. Interferons
    • 14.2.3. Recombinant Peptides
  • 14.3. Middle East & Africa Biosimilars Market Value Forecast, by Indication, 2017-2031
    • 14.3.1. Chronic Diseases
    • 14.3.2. Oncology
    • 14.3.3. Autoimmune Diseases
    • 14.3.4. Infectious Diseases
    • 14.3.5. Blood Disorders
    • 14.3.6. Growth Hormone Deficiency
    • 14.3.7. Others
  • 14.4. Middle East & Africa Biosimilars Market Value Forecast, by Country/Sub-region, 2017-2031
    • 14.4.1. GCC Countries
    • 14.4.2. South Africa
    • 14.4.3. Rest of Middle East & Africa
  • 14.5. Middle East & Africa Biosimilars Market Attractiveness Analysis
    • 14.5.1. By Product
    • 14.5.2. By Indication
    • 14.5.3. By Country/Sub-region

15. Competition Landscape

  • 15.1. Competition Matrix
  • 15.2. Market Share Analysis, by Company, 2021
  • 15.3. Company Profiles
    • 15.3.1. Pfizer, Inc.
      • 15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.1.2. Financial Overview
      • 15.3.1.3. Product Portfolio
      • 15.3.1.4. Strategic Overview
      • 15.3.1.5. SWOT Analysis
    • 15.3.2. Intas Pharmaceuticals Ltd.
      • 15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.2.2. Financial Overview
      • 15.3.2.3. Product Portfolio
      • 15.3.2.4. Strategic Overview
      • 15.3.2.5. SWOT Analysis
    • 15.3.3. Biocon
      • 15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.3.2. Financial Overview
      • 15.3.3.3. Product Portfolio
      • 15.3.3.4. Strategic Overview
      • 15.3.3.5. SWOT Analysis
    • 15.3.4. Dr. Reddy's Laboratories Ltd.
      • 15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.4.2. Financial Overview
      • 15.3.4.3. Product Portfolio
      • 15.3.4.4. Strategic Overview
      • 15.3.4.5. SWOT Analysis
    • 15.3.5. Teva Pharmaceutical Industries Ltd.
      • 15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.5.2. Financial Overview
      • 15.3.5.3. Product Portfolio
      • 15.3.5.4. Strategic Overview
      • 15.3.5.5. SWOT Analysis
    • 15.3.6. Sandoz International GmbH (A Novartis Division)
      • 15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.6.2. Financial Overview
      • 15.3.6.3. Product Portfolio
      • 15.3.6.4. Strategic Overview
      • 15.3.6.5. SWOT Analysis
    • 15.3.7. Celltrion, Inc.
      • 15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.7.2. Financial Overview
      • 15.3.7.3. Product Portfolio
      • 15.3.7.4. Strategic Overview
      • 15.3.7.5. SWOT Analysis
    • 15.3.8. Amgen, Inc.
      • 15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.8.2. Financial Overview
      • 15.3.8.3. Product Portfolio
      • 15.3.8.4. Strategic Overview
      • 15.3.8.5. SWOT Analysis
    • 15.3.9. STADA Arzneimittel AG
      • 15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.9.2. Financial Overview
      • 15.3.9.3. Product Portfolio
      • 15.3.9.4. Strategic Overview
      • 15.3.9.5. SWOT Analysis
    • 15.3.10. Apotex Inc. (Apobiologix)
      • 15.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.10.2. Financial Overview
      • 15.3.10.3. Product Portfolio
      • 15.3.10.4. Strategic Overview
      • 15.3.10.5. SWOT Analys

List of Tables

  • Table 01: Pipeline Analysis - Biosimilars
  • Table 02: Global Biosimilars Market Value (US$ Bn) Forecast, by Product, 2017-2031
  • Table 03: Global Biosimilars Market Value (US$ Bn) Forecast, by Recombinant Glycosylated Proteins, 2017-2031
  • Table 04: Global Biosimilars Market Value (US$ Bn) Forecast, by Recombinant Non-glycosylated Proteins, 2017-2031
  • Table 05: Global Biosimilars Market Value (US$ Bn) Forecast, by Indication, 2017-2031
  • Table 06: Global Biosimilars Market Value (US$ Bn) Forecast, by Region, 2017-2031
  • Table 07: North America Biosimilars Market Value (US$ Bn) Forecast, by Country, 2017-2031
  • Table 08: North America Biosimilars Market Value (US$ Bn) Forecast, by Product Type, 2017-2031
  • Table 09: North America Biosimilars Market Value (US$ Bn) Forecast, by Recombinant Glycosylated Proteins, 2017-2031
  • Table 10: North America Biosimilars Market Value (US$ Bn) Forecast, by Recombinant Non-glycosylated Proteins, 2017-2031
  • Table 11: North America Biosimilars Market Value (US$ Bn) Forecast, by Indication, 2017-2031
  • Table 12: Europe Biosimilars Market Value (US$ Bn) Forecast, by Country/Sub-region, 2017-2031
  • Table 13: Europe Biosimilars Market Value (US$ Bn) Forecast, by Product Type, 2017-2031
  • Table 14: Europe Biosimilars Market Value (US$ Bn) Forecast, by Recombinant Glycosylated Proteins, 2017-2031
  • Table 15: Europe Biosimilars Market Value (US$ Bn) Forecast, by Recombinant Non-glycosylated Proteins, 2017-2031
  • Table 16: Europe Biosimilars Market Value (US$ Bn) Forecast, by Indication, 2017-2031
  • Table 17: Asia Pacific Biosimilars Market Value (US$ Bn) Forecast, by Country/Sub-region, 2017-2031
  • Table 18: Asia Pacific Biosimilars Market Value (US$ Bn) Forecast, by Product, 2017-2031
  • Table 19: Asia Pacific Biosimilars Market Value (US$ Bn) Forecast, by Recombinant Glycosylated Proteins, 2017-2031
  • Table 20: Asia Pacific Biosimilars Market Value (US$ Bn) Forecast, by Recombinant Non-glycosylated Proteins, 2017-2031
  • Table 21: Asia Pacific Biosimilars Market Value (US$ Bn) Forecast, by Indication, 2017-2031
  • Table 22: Latin America Biosimilars Market Value (US$ Bn) Forecast, by Country/Sub-region, 2017-2031
  • Table 23: Latin America Biosimilars Market Value (US$ Bn) Forecast, by Product, 2017-2031
  • Table 24: Latin America Biosimilars Market Value (US$ Bn) Forecast, by Recombinant Glycosylated Proteins, 2017-2031
  • Table 25: Latin America Biosimilars Market Value (US$ Bn) Forecast, by Recombinant Non-glycosylated Proteins, 2017-2031
  • Table 26: Latin America Biosimilars Market Value (US$ Bn) Forecast, by Indication, 2017-2031
  • Table 27: Middle East & Africa Biosimilars Market Value (US$ Bn) Forecast, by Country/Sub-region, 2017-2031
  • Table 28: Middle East & Africa Biosimilars Market Value (US$ Bn) Forecast, by Product, 2017-2031
  • Table 29: Middle East & Africa Biosimilars Market Value (US$ Bn) Forecast, by Recombinant Glycosylated Proteins, 2017-2031
  • Table 30: Middle East & Africa Biosimilars Market Value (US$ Bn) Forecast, by Recombinant Non-glycosylated Proteins, 2017-2031
  • Table 31: Middle East & Africa Biosimilars Market Value (US$ Bn) Forecast, by Indication, 2017-2031

List of Figures

  • Figure 01: Global Biosimilars Market Snapshot
  • Figure 02: Global Biosimilars Market Value (US$ Bn) by Region, 2021 and 2031
  • Figure 03: Global Biosimilars Market Value (US$ Bn) Forecast, 2021-2031
  • Figure 04: Global Biosimilars Market Value Share (%), by Product, 2021
  • Figure 05: Global Biosimilars Market Value Share (%), by Indication, 2021
  • Figure 06: Global Biosimilars Market Value Share (%), by Region, 2021
  • Figure 07: Entry Barriers to Biosimilars Market
  • Figure 08: Factors Driving the Adoption of Biosimilars
  • Figure 09: Biosimilar Approval Process - US
  • Figure 10: Data Requirements for Biosimilar Approval in Europe
  • Figure 11: Regulations for Biosimilar Approval in Japan
  • Figure 12: Regulations for Biosimilar Approval in India
  • Figure 13: Regulations for Biosimilar Approval in Brazil
  • Figure 14: Regulations for Biosimilar Approval in Saudi Arabia
  • Figure 15: Biosimilars Market - Key Product Launches
  • Figure 16: Global Biosimilars Market Value Share Analysis, by Product, 2021 and 2031
  • Figure 17: Global Biosimilars Market Value Share Analysis, by Recombinant Glycosylated Proteins, 2021 and 2031
  • Figure 18: Global Biosimilars Market Value Share Analysis, by Recombinant Non-glycosylated Proteins, 2021 and 2031
  • Figure 19: Global Biosimilars Market Value (US$ Bn) Forecast, by Recombinant Glycosylated Proteins, 2017-2031
  • Figure 20: Global Biosimilars Market Value (US$ Bn) Forecast, by Recombinant Non-glycosylated Proteins, 2017-2031
  • Figure 21: Global Biosimilars Market Value (US$ Bn) Forecast, by Recombinant Peptides, 2017-2031
  • Figure 22: Global Biosimilars Market Value (US$ Bn) Forecast, by Monoclonal Antibodies, 2017-2031
  • Figure 23: Global Biosimilars Market Value (US$ Bn) Forecast, by Erythropoietin, 2017-2031
  • Figure 24: Global Biosimilars Market Value (US$ Bn) Forecast, by Others, 2017-2031
  • Figure 25: Global Biosimilars Market Value (US$ Bn) Forecast, by Insulin, 2017-2031
  • Figure 26: Global Biosimilars Market Value (US$ Bn) Forecast, by Granulocyte Colony Stimulating Factor, 2017-2031
  • Figure 27: Global Biosimilars Market Value (US$ Bn) Forecast, by Recombinant Human Growth Factor, 2017-2031
  • Figure 28: Global Biosimilars Market Value (US$ Bn) Forecast, by Interferons, 2017-2031
  • Figure 29: Global Biosimilars Market Attractiveness Analysis, by Product, 2021 and 2031
  • Figure 30: Global Biosimilars Market Attractiveness Analysis, by Recombinant Glycosylated Proteins, 2021 and 2031
  • Figure 31: Global Biosimilars Market Attractiveness Analysis, by Recombinant Non-glycosylated Proteins, 2021 and 2031
  • Figure 32: Global Biosimilars Market Value Share Analysis, by Indication, 2021 and 2031
  • Figure 33: Global Biosimilars Market Value (US$ Bn) Forecast, by Chronic Diseases, 2017-2031
  • Figure 34: Global Biosimilars Market Value (US$ Bn) Forecast, by Oncology, 2017-2031
  • Figure 35: Global Biosimilars Market Value (US$ Bn) Forecast, by Autoimmune Diseases, 2017-2031
  • Figure 36: Global Biosimilars Market Value (US$ Bn) Forecast, by Infectious Diseases, 2017-2031
  • Figure 37: Global Biosimilars Market Value (US$ Bn) Forecast, by Blood Disorders, 2017-2031
  • Figure 38: Global Biosimilars Market Value (US$ Bn) Forecast, by Growth Hormone Deficiency, 2017-2031
  • Figure 39: Global Biosimilars Market Value (US$ Bn) Forecast, by Others, 2017-2031
  • Figure 40: Global Biosimilars Market Attractiveness Analysis, by Indication, 2021-2031
  • Figure 41: Global Biosimilars Market: Regional Outlook
  • Figure 42: Global Biosimilars Market Value Share Analysis, by Region, 2021 and 2031
  • Figure 43: Global Biosimilars Market Attractiveness Analysis, by Region, 2021-2031
  • Figure 44: North America Biosimilars Market Value (US$ Bn) Forecast, 2017-2031
  • Figure 45: North America Biosimilars Market Value Share Analysis, by Country, 2021 and 2031
  • Figure 46: North America Biosimilars Market Value Share Analysis, by Product, 2021 and 2031
  • Figure 47: North America Biosimilars Market Value Share Analysis, by Recombinant Glycosylated Proteins, 2021 and 2031
  • Figure 48: North America Biosimilars Market Value Share Analysis, by Recombinant Non-glycosylated Proteins, 2021 and 2031
  • Figure 49: North America Biosimilars Market Value Share Analysis, by Indication, 2021 and 2031
  • Figure 50: North America Biosimilars Market Attractiveness Analysis, by Product, 2021 and 2031
  • Figure 51: North America Biosimilars Market Attractiveness Analysis, by Recombinant Glycosylated Proteins, 2021 and 2031
  • Figure 52: North America Biosimilars Market Attractiveness Analysis, by Recombinant Non-glycosylated Proteins, 2021 and 2031
  • Figure 53: North America Biosimilars Market Attractiveness Analysis, by Indication, 2021 and 2031
  • Figure 54: North America Biosimilars Market Attractiveness Analysis, by Country, 2021 and 2031
  • Figure 55: Europe Biosimilars Market Value (US$ Bn) and Y-o-Y Growth (%) Forecast, 2017-2031
  • Figure 56: Europe Biosimilars Market Value Share Analysis, by Country/Sub-region, 2021 and 2031
  • Figure 57: Europe Biosimilars Market Value Share Analysis, by Product, 2021 and 2031
  • Figure 58: Europe Biosimilars Market Value Share Analysis, by Recombinant Glycosylated Proteins, 2021 and 2031
  • Figure 59: Europe Biosimilars Market Value Share Analysis, by Recombinant Non-glycosylated Proteins, 2021 and 2031
  • Figure 60: Europe Biosimilars Market Value Share Analysis, by Indication, 2021 and 2031
  • Figure 61: Europe Biosimilars Market Attractiveness Analysis, by Product, 2021 and 2031
  • Figure 62: Europe Biosimilars Market Attractiveness Analysis, by Recombinant Glycosylated Proteins, 2021 and 2031
  • Figure 63: Europe Biosimilars Market Attractiveness Analysis, by Recombinant Non-glycosylated Proteins, 2021 and 2031
  • Figure 64: Europe Biosimilars Market Attractiveness Analysis, by Indication, 2021 and 2031
  • Figure 65: Europe Biosimilars Market Attractiveness Analysis, by Country/Sub-region, 2021 and 2031
  • Figure 66: Asia Pacific Biosimilars Market Value (US$ Bn) and Y-o-Y Growth (%) Forecast, 2017-2031
  • Figure 67: Asia Pacific Biosimilars Market Value Share Analysis, by Country/Sub-region, 2021 and 2031
  • Figure 68: Asia Pacific Biosimilars Market Value Share Analysis, by Product, 2021 and 2031
  • Figure 69: Asia Pacific Biosimilars Market Value Share Analysis, by Recombinant Glycosylated Proteins, 2021 and 2031
  • Figure 70: Asia Pacific Biosimilars Market Value Share Analysis, by Recombinant Non-glycosylated Proteins, 2021 and 2031
  • Figure 71: Asia Pacific Biosimilars Market Value Share Analysis, by Indication, 2021 and 2031
  • Figure 72: Asia Pacific Biosimilars Market Attractiveness Analysis, by Product, 2021 and 2031
  • Figure 73: Asia Pacific Biosimilars Market Attractiveness Analysis, by Recombinant Glycosylated Proteins, 2021 and 2031
  • Figure 74: Asia Pacific Biosimilars Market Attractiveness Analysis, by Recombinant Non-glycosylated Proteins, 2021 and 2031
  • Figure 75: Asia Pacific Biosimilars Market Attractiveness Analysis, by Indication, 2021 and 2031
  • Figure 76: Asia Pacific Biosimilars Market Attractiveness Analysis, by Country/Sub-region, 2021 and 2031
  • Figure 77: Latin America Biosimilars Market Value (US$ Bn) and Y-o-Y Growth (%) Forecast, 2017-2031
  • Figure 78: Latin America Biosimilars Market Value Share Analysis, by Country/Sub-region, 2021 and 2031
  • Figure 79: Latin America Biosimilars Market Value Share Analysis, by Product, 2021 and 2031
  • Figure 80: Latin America Biosimilars Market Value Share Analysis, by Recombinant Glycosylated Proteins, 2021 and 2031
  • Figure 81: Latin America Biosimilars Market Value Share Analysis, by Recombinant Non-glycosylated Proteins, 2021 and 2031
  • Figure 82: Latin America Biosimilars Market Value Share Analysis, by Indication, 2021 and 2031
  • Figure 83: Latin America Biosimilars Market Attractiveness Analysis, by Product, 2021 and 2031
  • Figure 84: Latin America Biosimilars Market Attractiveness Analysis, by Recombinant Glycosylated Proteins, 2021 and 2031
  • Figure 85: Latin America Biosimilars Market Attractiveness Analysis, by Recombinant Non-glycosylated Proteins, 2021 and 2031
  • Figure 86: Latin America Biosimilars Market Attractiveness Analysis, by Indication, 2021 and 2031
  • Figure 87: Latin America Biosimilars Market Attractiveness Analysis, by Country/Sub-region, 2021 and 2031
  • Figure 88: Middle East & Africa Biosimilars Market Value (US$ Bn) and Y-o-Y Growth (%) Forecast, 2017-2031
  • Figure 89: Middle East & Africa Biosimilars Market Value Share Analysis, by Country/Sub-region, 2021 and 2031
  • Figure 90: Middle East & Africa Biosimilars Market Value Share Analysis, by Product, 2021 and 2031
  • Figure 91: Middle East & Africa Biosimilars Market Value Share Analysis, by Recombinant Glycosylated Proteins, 2021 and 2031
  • Figure 92: Middle East & Africa Biosimilars Market Value Share Analysis, by Recombinant Non-glycosylated Proteins, 2021 and 2031
  • Figure 93: Middle East & Africa Biosimilars Market Value Share Analysis, by Indication, 2021 and 2031
  • Figure 94: Middle East & Africa Biosimilars Market Attractiveness Analysis, by Product, 2021 and 2031
  • Figure 95: Middle East & Africa Biosimilars Market Attractiveness Analysis, by Recombinant Glycosylated Proteins, 2021 and 2031
  • Figure 96: Middle East & Africa Biosimilars Market Attractiveness Analysis, by Recombinant Non-glycosylated Proteins, 2021 and 2031
  • Figure 97: Middle East & Africa Biosimilars Market Attractiveness Analysis, by Indication, 2021 and 2031
  • Figure 98: Middle East & Africa Biosimilars Market Attractiveness Analysis, by Country/Sub-region, 2021 and 2031
  • Figure 99: Global Biosimilars Market Share Analysis, by Company, 2018